Publication:
Oral Immunotherapy for Food Allergy: Towards a New Horizon

Thumbnail Image

Date

2013

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Khoriaty, Evelyne Nassim, and Dale T. Umetsu. 2013. Oral immunotherapy for food allergy: towards a new horizon. Allergy, Asthma & Immunology Research 5(1): 3-15.

Research Data

Abstract

Food allergy has increased dramatically in prevalence over the past decade in westernized countries, and is now a major public health problem. Unfortunately for patients with food allergy, there is no effective therapy beyond food allergen avoidance, and rapid medical treatment for accidental exposures. Recently, oral immunotherapy (OIT) has been investigated as a treatment for this problem. In this review, we will discuss the progress in developing OIT for food allergy, including a novel approach utilizing Xolair (anti-IgE monoclonal antibody, omalizumab) in combination with OIT. This combination may enhance both the safety and efficacy of oral immunotherapy, and could lead to a widely available and safe therapy for food allergy.

Description

Keywords

Oral immunotherapy, omalizumab, anti-IgE, xolair, food allergy, desensitization

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories

Story
Oral Immunotherapy for Food Allergy: Towards… : DASH Story 2014-05-20
I am evaluating immunotherapy options for myself and family. Being able to access works in the field by scholars from my home is MUCH simpler then having to go to my library or university library. It turned my research from 3 hours to 3 minutes . Thanks!